阿托伐他汀与氯吡格雷相互作用的争议及评价
被引量:7
摘要
冠心病(急性冠脉综合征)是以动脉粥样硬化和血栓形成为基础的疾病.临床预防和治疗中,抗动脉粥样硬化和抗血栓治疗是两项基本的而且是最重要的治疗措施.
出处
《中国医药导刊》
2004年第1期56-58,共3页
Chinese Journal of Medicinal Guide
参考文献20
-
1Malhotra HS, Goa KL. Atorvastatin: An Updated Review of its Pharmacological Properties and Use in Dyslipidaemia. Drugs,2001 ; 61(12) 1835 - 1881.
-
2Cavusoglu, Erdal, Cheng, et al. Clopidogrel in the Management of Ischemic Heart Disease. HEART DISEASE, 2003;5(2) 144-152.
-
3Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug-Drug Interaction. Circulation, 2003; 107(1):32-37.
-
4Quinn M J, FitzGerald DJ. Ticlopidine and clopidogrel. Circulation,1999; 100(15) : 1667 - 1672.
-
5Clarke TA , Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P4503A and is inhibited by atorvastatin. Drug Metab Dispos, 2003; 31 : 53 - 59.
-
6Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost,2000; 84:891 - 896.
-
7Jarvis Blair, Simpson Kerryn. Clopidogrel : A Review of its Use in the Prevention of Atherothrombosis. Drugs, 60(2) : 347-377.
-
8Kearney AS, Crawford LF, Mehta SC, et al. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxuacid forms of the HMG - CoA reductase inhibitor, CI - 981.Pharm Res, 1993; 10:1461 - 1465.
-
9Lea AP, McTavish D. Atorvastatin : a review of its pharmacology and therapeutic potential in the management of hyperlipidemias.Drugs, 1997;53:828 - 847.
-
10Thummel KE,Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol, 1998; 38: 389 - 430.
同被引文献96
-
1Eric L Eisenstein, DBA,Kevin J. Anstrom, PhD,David F. Kong, MD,Linda K. Shaw, MS,Robert H. Tuttle, MSPH,Daniel B. Mark, MD, MPH,Judith M. Kramer, MD, MS,Robert A. Harrington, MD,David B. Matchar, MD,David E. Kandzari, MD 1,Eric D. Peterson, MD, MPH,Kevin A. Schulman, MD,Robert M. Califf, MD,李呈亿(译),David E. Kandzari, MD.氯吡格雷的使用与药物洗脱支架植入后远期临床结果[J].美国医学会杂志(中文版),2007,26(3):131-139. 被引量:59
-
2Briguori C, Visconti G, Focaccio A,et al. Novel approaches for pre- venting or limiting events(Naples) Ⅱ trial impact of a single high loading dose of atorvastatin on periproeedural myocardial infarction [J]. J Am Coll Cardiol,2009,54(23) :2157- 2163.
-
3Williams D, Feely J. Pharmacokinetic- pharmacodynamic drug in- teractions with HMG - CoA reductase inhibitors[J]. Clin Pharma- cokinet,2002,41(5) :343 - 370.
-
4Clarke TA,Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin [J]. Drug Metab Dispos,2003,31(1) :53 - 59.
-
5Lau WC,Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug - drug interaction[J]. Circulation, 2003,107(1) : 32 - 37.
-
6Saw J, Steinhubl SR, Berger PB. Lack of adverse clopidogrel - at- rorvastatin clinical interaction from secondary analysis of a ran- domized, placebo - controlled clopidogrei trial [J]. Circulation, 2003,108(8) : 921 - 924.
-
7Gorchakova O, yon Beckerath N, Gawaz M. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting[J]. Eur heart J,2004,25(21): 1989 - 1902.
-
8Savi P,Pereillo JM, Uzabiaga MF,et al. Identification and biologi cal activity of tb.e active metabolite of clopidogrel[J]. Thromb Hae most,2000,84(5) :891 - 896.
-
9Laufs U,Gertz K,Huang P,etal. Atorvastatin upregulates type nitric oxide synthase in thrombocytes, decreases platelet activa- tion,and protects from cerebral ischemia in normocholesterolemic mice[J]. Stroke,2000,31(10):2442 - 2449.
-
10Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronarysyndrome [J]. Am J Cardiol, 2008, 101: 1088-1093.
引证文献7
-
1吴桂萍,李田昌.氯吡格雷研究的最新进展[J].临床荟萃,2006,21(7):516-519. 被引量:59
-
2张国明,王禹.氯吡格雷抵抗的研究进展[J].中国循环杂志,2006,21(5):398-400.
-
3熊日成,向定成.冠心病患者应用双联抗血小板药物新进展[J].广东医学,2008,29(11):1927-1928.
-
4李献玉,郝少君.氯吡格雷药物相互作用研究进展[J].中国医院药学杂志,2011,31(13):1123-1127. 被引量:15
-
5李馨,刘云宝,黄超联,苗立夫,李莉娜,孙晓艳.PCI围术期单次高负荷量阿托伐他汀对抗血小板药物的影响[J].中西医结合心脑血管病杂志,2011,9(8):923-924. 被引量:2
-
6赵黎佳,徐晓薇,杜凤和,魏欣.血栓弹力图测定老年急性冠脉综合征患者氯吡格雷抵抗的临床观察[J].医学临床研究,2012,29(10):1889-1891. 被引量:3
-
7黄宇,黄峥嵘.他汀类药物联合替格瑞洛抗血小板作用的影响[J].健康之路,2017,0(7):1-1.
二级引证文献79
-
1刘金敬,李丰升,聂忆秋.氯吡格雷治疗中青年脑梗死的疗效观察[J].医学信息(医学与计算机应用),2014,0(12):230-231.
-
2刘璇,黄雪珊.氯吡格雷对异种移植心脏急性血管性排斥反应的影响[J].福建医科大学学报,2006,40(6):572-574.
-
3张娆.氯吡格雷治疗中青年脑梗死的临床疗效分析[J].中国医学前沿杂志(电子版),2013,5(9):74-76.
-
4杨翠娈,石家庆.氯吡格雷联合低分子肝素钙治疗短暂性脑缺血发作的临床观察[J].广西医科大学学报,2010,27(6):913-914. 被引量:13
-
5童丽军,季乃军,胡昌盛,梅益斌,陈东海,王成尧.氯吡格雷对PCI TXB2 6-K-PGF1α和PTINR的干预影响[J].浙江临床医学,2007,9(6):757-757.
-
6韩志武,李靖,王芳,徐友平,姚国乾.氯吡格雷用于尿毒症动静脉内瘘术后维护的疗效观察[J].内科急危重症杂志,2007,13(3):164-164. 被引量:10
-
7刘立新,杨保刚,王肖铭,朱海勇.氯吡格雷联合低分子肝素钙治疗进展性脑梗死临床观察[J].现代实用医学,2007,19(10):802-803. 被引量:5
-
8杨琴,赵倡武.氯吡格雷治疗不稳定型心绞痛临床观察[J].中国误诊学杂志,2008,8(33):8111-8112. 被引量:1
-
9孙鹏,金英顺.高效液相色谱法快速测定硫酸氯吡格雷片的含量[J].中国医院药学杂志,2008,28(22):1968-1970. 被引量:1
-
10赵伟丽,崔其福.丹红注射液联合氯吡格雷治疗进展性卒中的临床研究[J].辽宁中医杂志,2008,35(12):1876-1877.
-
1王令嘉,严序炳,王颖.小剂量阿斯匹林抗血栓治疗的进展[J].安徽医学,1991,12(2):45-47.
-
2V W Steinijans,李鸿彬.生物等效性研究的争议[J].药学进展,1993,17(1):33-36.
-
3争议[J].中国处方药,2005(11):60-60.
-
4王瑛,单永常.阿司匹林在心脑血管疾病中的应用[J].天津药学,1996,8(3):30-31. 被引量:3
-
5柴中元.柴胡补劳之争评议[J].甘肃中医学院学报,1989(3):38-39.
-
6黄震华.伴有心房颤动的急性冠状动脉综合征患者抗血栓治疗[J].中国新药与临床杂志,2016,35(2):102-109.
-
7尹代江,舒娴.糖皮质激素在慢性阻塞性肺病加重期的应用价值[J].临床荟萃,2004,19(6):334-335. 被引量:6
-
8半个世纪的争议——苯二氮()类药物临床应用50年[J].中国处方药,2003,2(2):66-67.
-
9殷琪琦 ,罗心平 .心力衰竭的治疗中如何使用阿司匹林[J].心血管病学进展,2004,25(1):41-43. 被引量:2
-
10陆志城.对儿童应用喹诺酮类药物的探讨[J].广东药学,2001,11(1):11-12. 被引量:2